ArticleClinical kidney journal2025
Tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD): a multicenter real life Italian experience.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment of Autosomal Dominant Polycystic Kidney Disease: Integrating Clinical Practice Guidelines, Patient Perspectives, and Real-World Effectiveness.Journal of the American Society of Nephrology : JASN · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tolvaptan is the only disease-modifying treatment approved to slow kidney disease progression in autosomal dominant polycystic kidney disease (ADPKD). Data on tolvaptan in ADPKD outside of clinical trials are limited, usually deal with short-term observations and are characterized by a drop-out rate of 21%-56%. Methods: In this retrospective, observational, multicenter study enrolling 122 Italian patients with ADPKD and rapid progressive renal disease, we evaluated the tolerability and side effects of tolvaptan treatment in a real-life setting. A personalized treatment strategy, based on an accurate patient selection and a strict clinical and laboratory monitoring, was applied. Results: During a median follow-up of 34.0 (interquartile range 17.3; -46.5) months the overall adherence on tolvaptan was 82.0%. Permanent withdrawal was reported in 22/122 patients (18.0%) after a mean of 34.4 ± 18.0 months; the main reasons for drug permanent withdrawal were onset of kidney failure in 7/122 (5.7%), poor tolerance to aquaresis in 4/122 (3.3%), family planning in 3/122 (2.5%) and liver function test elevation in 2/122 patients (1.6%). Temporary discontinuation was observed in 35/122 patients (28.7%) and in most cases it was not related to drug side effects. In order to evaluate tolvaptan eligibility, historic estimated glomerular filtration rate decline was the most inclusive criteria (92.9%) when compared with Mayo Imaging Classification (89.7%) and Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) Score (22.6%). Conclusion: This real-life study confirms the feasibility, safety, and tolerability of tolvaptan treatment. In order to overcome the challenges of tolvaptan treatment, our experience suggests that a dedicated PKD team may play a key role in implementing strategies focused to reduce drop-out and achieve treatment success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.